Physician profile
Jami Swenson
NPI 1427431386
$1,681.98
in general payments reported to CMS, 2019-2025
13 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $84.17 · 2021: $245 · 2022: $342 · 2023: $416 · 2024: $320 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $690.22 | 2019-2024 | Acuvue |
| Bausch & Lomb Americas INC. | $236.63 | 2023-2025 | Infuse, Biotrue One Day, Alden Scleral Zenlens |
| Alcon Vision LLC | $141.60 | 2019-2025 | Precision 1, Precision7 |
| Sun Pharmaceutical Industries INC. | $141.35 | 2020-2024 | |
| Oyster Point Pharma, INC. | $113.41 | 2022-2024 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $83.19 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $79.23 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $50.89 | 2021-2022 | |
| Glaukos Corporation | $49.65 | 2021 | |
| Dompe US, INC. | $30.99 | 2025 | Oxervate |
| Allergan, INC. | $24.91 | 2021 | |
| Shire North American Group INC | $21.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jami Swenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.